FDA Accepts Resubmission of Eisai Inc.'s Perampanel New Drug Application

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai’s resubmission of the New Drug Application (NDA) for perampanel (E2007), an investigational drug, for the treatment of partial-onset seizures associated with epilepsy. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of October 22, 2012.